Drug class
Prekallikrein-directed antisense oligonucleotide (ASO); GalNAc-conjugated RNA-targeting therapy
Mechanism of action
A GalNAc-conjugated antisense oligonucleotide that binds prekallikrein (KLKB1) mRNA and induces RNase H1-mediated degradation, reducing prekallikrein protein and downstream plasma kallikrein/bradykinin generation.
General use cases
- Prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older under the US FDA indication approved August 21 2025
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
